Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.

ABSTRACT:

Background

Africa has some of the highest cervical cancer incidence and mortality rates globally. Burkina Faso launched a human papillomavirus (HPV) vaccination programme for 9-year-old girls in 2022 with support from Gavi, the Vaccine Alliance (Gavi). An economic evaluation of HPV vaccination is required to help sustain investment and inform decisions about optimal HPV vaccine choices.

Methods

We used a proportionate outcomes static cohort model to evaluate the potential impact and cost-effectiveness of HPV vaccination for 9-year-old girls over a ten-year period (2022-2031) in Burkina Faso. The primary outcome measure was the cost (2022 US$) per disability-adjusted life year (DALY) averted from a limited societal perspective (including all vaccine costs borne by the governm

SUBMITTER: Kiendrebeogo JA 

PROVIDER: S-EPMC10693094 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature